An Oklahoma-based non-profit hospital is the latest medical facility to sue pharmaceutical giant Genentech,accusing the company of shipping less than the labeled claim of the anticancer drug trastuzumab (Herceptin) in each multi-dose vial.
An Oklahoma-based non-profit hospital, Comanch County Memorial Hospital, is the latest medical facility to sue pharmaceutical giant Genentech, and the Swiss corporation Roche, which is the parent company. So far, about a dozen lawsuits have been filed against Genentech, accusing the company of shipping less than the labeled claim of the anticancer drug trastuzumab (Herceptin) in each vial.
The multi-dose vial of trastuzumab is shipped as a freeze dried powder, to be reconstituted by the end user prior to administration for breast cancer treatment. However, according to a this most recent lawsuit filed in the US District Court for the Northern District of California, Genentech misrepresented the amount or concentration of trastuzumab in each vial, which resulted in the hospital buying more of this expensive drug, which has a limited shelf life (28 days) once reconstituted in benzyl alcohol as indicated on the label. Any unused drug that is reconstituted in water has to be discarded immediately and cannot be stored.
A targeted therapy, the antibody binds the HER-2 receptor which is often overexpressed in several cancers, especially breast cancer. Initially approved for treatment of HER-2—positive breast cancer in the adjuvant setting, trastuzumab was subsequently approved for use in early stages of breast cancer, as well as advanced gastric and gastroesophageal cancer. And the treatment is not cheap—52 infusions over an entire year cost is the standard treatment, which costs about $70,000. Further, wholesale cost discounts availed by oncology clinics and hospitals have been disappearing as the drug is now available only from specialty distributors. This translates into a significant cost burden on clinics and ultimately, the patient.
In their lawsuit, the hospital explains that after following the company’s directions on reconstitution to achieve a concentration of 21 mg/ml of trastuzumab in the multi-dose vial, the final volume of the solution is less (20.2 ml) than what it should be (20.95 ml). This, the plaintiff claims, could either mean that each vial has less drug or that the concentration of the final solution is not the required 21 mg/ml. Eventually, the shortfall requires hospitals and clinics to purchase additional vials.
Nine other cancer care centers have filed a similar lawsuit against the company earlier this year, and one of the plaintiffs, Tennessee Oncology is pursuing monetary damage to cover the costs of the additional trastuzumab that it was forced to purchase.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More